Mei Ri Jing Ji Xin Wen·2025-05-13 23:34Group 1 - Tonghua Dongbao has received approval from Nicaragua's National Health Regulatory Authority for its recombinant human insulin injection, which is expected to enhance the company's international market presence and brand image [1] - The diabetes patient population in Nicaragua is projected to reach 377,000 by 2024, with an 8.7% prevalence rate among adults aged 20-79, indicating a significant market opportunity for the company [1] - The average annual expenditure per diabetes patient in Nicaragua is estimated at $587, highlighting the potential revenue generation from the new product [1] Group 2 - Haobor's response to the 2024 annual report inquiry reflects the company's commitment to regulatory compliance and transparency, addressing concerns regarding its distribution model and dealer management [2] - The detailed analysis of dealer numbers and management policies demonstrates the stability and rationality of the company's business model, which may alleviate investor concerns [2] - Continuous optimization of dealer management is expected to provide strong support for the company's long-term development [2] Group 3 - Kangji Medical has decided to terminate the sale of a subsidiary and has reached a settlement agreement with the buyer, which includes the return of company records and a refund of 5 million yuan [3] - The company expects to realize approximately 39.3 million yuan in gains from a land recovery agreement with government agencies, indicating effective management of complex transactions [3] - The resolution of this transaction is likely to stabilize investor confidence and positively impact the company's long-term growth prospects [3] Group 4 - Jincheng Pharmaceutical has signed a licensing and distribution agreement with UK-based Theramex HQ UK Limited for the hormone replacement therapy product Bijuva, aimed at addressing estrogen deficiency symptoms in postmenopausal women [4] - This collaboration aligns with the company's strategy to enhance its offerings in women's health and strengthen partnerships with international pharmaceutical firms [4] - The agreement is expected to expand the company's product portfolio in the women's health sector and improve its brand influence in this market [4]